U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International

Reuters05-16

May 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AN2 Therapeutics, Ecolab and RPM International on Thursday.

HIGHLIGHTS

* AN2 Therapeutics Inc : Evercore ISI cuts target price to $2 from

$7

* Biolife Solutions Inc : Maxim Group raises target price to $30

from $25

* Ecolab Inc : Evercore ISI raises target price to $250 from $195

* RPM International Inc : Evercore ISI raises target price to $130

from $110

* Third Harmonic Bio Inc : Jefferies raises target price to $15

from $8.1

Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.

* AN2 Therapeutics Inc : Evercore ISI cuts target price to $2 from $7

* Analog Devices Inc : Oppenheimer raises target price to $245 from $215

* Ashland Inc : Evercore ISI raises target price to $100 from $95

* Axalta Coating Systems Ltd : Jefferies raises target price to $39 from $36

* Biolife Solutions Inc : Maxim Group raises target price to $30 from $25

* Cabaletta Bio Inc : Jefferies cuts target price to $31 from $36

* Celanese Corp : Evercore ISI raises target price to $170 from $150

* Cisco : Jefferies raises target price to $56 from $55

* Devon Energy Corp : Gerdes Energy Research raises to buy from neutral

* Dynatrace Inc : BTIG cuts target price to $57 from $66

* Dynatrace Inc : RBC cuts target price to $60 from $66

* Dynatrace Inc : TD Cowen raises target price to $60 from $58

* Eastman Chemical Co : Evercore ISI raises target price to $118 from $98

* Ecolab Inc : Evercore ISI raises target price to $250 from $195

* Enterprise Products Partners LP : JP Morgan cuts target price to $32 from $33

* Eos Energy Enterprises Inc : Evercore ISI cuts target price to $3 from $7

* Flowers Foods Inc : Stephens raises target price to $27 from $24

* Goodrx Holdings Inc : Leerink Partners raises target price to $12 from $11

* Hess Corp : Susquehanna raises target price to $167 from $164

* International Game Technology Plc : Jefferies cuts target price to $23 from $26

* Jack In the Box Inc : Stifel cuts target price to $60 from $75

* Kodiak Sciences Inc : Jefferies cuts target price to $4 from $7

* Kosmos Energy Ltd : Jefferies raises target price to $7.65 from $7.3

* Manhattan Associates Inc : D.A. Davidson raises target price to $260 from $240

* Molina Healthcare Inc : Stephens cuts target price to $355 from $390

* Newmont : Bernstein cuts target price to $45 from $46

* Nextracker Inc : HSBC cuts target price to $60 from $65

* Olema Pharmaceuticals Inc : H.C. Wainwright raises target price to $30 from $28

* Perspective Therapeutics Inc : Jonestrading raises PT to $2.20 from $1.50

* Reviva Pharmaceuticals Holdings Inc : Maxim Group cuts PT to $6 from $18

* RPM International Inc : Evercore ISI raises target price to $130 from $110

* Savara Inc : Evercore ISI cuts target price to $7 from $10

* Southwestern Energy Co : Susquehanna raises target price to $8 from $7.50

* Starwood Property Trust Inc : Raymond James cuts target price to $23 from

$23.50

* Targa Resources Corp : RBC raises target price to $128 from $123

* Third Harmonic Bio Inc : Jefferies raises target price to $15 from $8.1

* Vislink Technologies Inc : Alliance Global Partners raises PT to $12 from $10

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment